A needle exchange program, now more commonly called a syringe services program (SSP), is a public health service that provides sterile needles and syringes to people who inject drugs. The core goal is straightforward: replace used needles with clean ones to prevent the spread of HIV, hepatitis C, and other bloodborne infections. These programs are associated with an approximately 50% reduction in new HIV and hepatitis C infections among participants.
But modern programs do far more than swap needles. They function as a front door to healthcare for people who often have no other point of contact with the medical system.
Services Beyond Sterile Needles
While syringe distribution is the defining feature, most programs offer a broad package of health services. A typical site provides screening for HIV, hepatitis C, sexually transmitted infections, and tuberculosis. Many distribute condoms, offer risk-reduction counseling, and connect participants to vaccinations for hepatitis A and B. Programs also refer people to mental health care, social services, and housing support.
One of the most significant additions in recent years is overdose prevention. In a 2019 CDC survey, 96% of SSPs with overdose education programs reported distributing naloxone, the medication that reverses opioid overdoses. Across those programs, more than 700,000 naloxone doses were given to roughly 230,000 people in a single 12-month period. That translates to about three doses per person, enough to keep on hand for emergencies and share with others nearby.
Perhaps most importantly, these programs serve as a bridge into substance use treatment. Multiple studies have found that SSP participants are significantly more likely than non-participants to enter methadone treatment, medically managed withdrawal, or other addiction treatment programs, and to eventually stop injecting altogether.
How Programs Actually Operate
Syringe services programs run through several delivery models. Fixed sites operate from a permanent location, often within a community health center, clinic, or dedicated storefront. These tend to offer the widest range of services because staff and resources are centralized. Mobile programs use vans or buses to reach people in areas without fixed sites, traveling on set schedules through neighborhoods with high need. Other models include pharmacy-based distribution, vending machines, peer-run exchanges, and partnerships with hospitals or homeless shelters.
Each model reaches a somewhat different population. Mobile programs tend to attract people who inject more frequently and face higher health risks, while pharmacy-based programs draw a broader mix. When a fixed site closes and only mobile services remain, research shows that basic contact with clients continues but the full range of services is harder to maintain. Many cities use a combination of models to cover as much ground as possible.
As of mid-2025, at least 522 syringe services programs operate across 43 states, Washington D.C., and Puerto Rico, based on self-reported data collected by the North American Syringe Exchange Network. The actual number is likely higher, since not all programs register with the directory.
The Evidence on HIV and Hepatitis C Prevention
Sharing needles is one of the most efficient ways to transmit bloodborne viruses. A single contaminated syringe can carry enough HIV or hepatitis C virus to infect another person. Syringe services programs interrupt that chain by ensuring people have access to sterile equipment for every injection.
The public health returns are well documented. SSPs are linked to a roughly 50% drop in new HIV and hepatitis C infections among people who inject drugs. Beyond providing clean needles, the on-site screening these programs offer catches infections early, when treatment is most effective and before further transmission occurs.
Cost Savings
Preventing even a single HIV infection carries enormous financial weight. Lifetime treatment costs for one person with HIV run close to $391,000 in the United States, along with an estimated loss of 9 to 21 years of life. A national economic model published in a peer-reviewed journal estimated that an additional $10 million invested in syringe services programs in a single year would avert 194 HIV infections and save $75.8 million in future treatment costs. Scaling that up to $50 million in new investment would prevent roughly 816 infections, about one-third of all new HIV cases tied to injection drug use annually, and save $319 million in treatment costs. That works out to a return of more than six dollars for every dollar spent.
Do These Programs Increase Drug Use?
This is the most persistent concern raised about needle exchange programs, and the evidence consistently points in one direction: no. The worry is that providing clean syringes makes injecting drugs easier or more appealing, drawing in new users or encouraging existing users to inject more often. Researchers have studied this question repeatedly, and no credible evidence supports it.
One of the strongest datasets comes from tracking methadone program admissions during and after the large-scale rollout of syringe exchanges. During that period, the number of people entering treatment who reported injecting actually decreased, while the number reporting non-injection drug use increased. The data are “clearly inconsistent,” as the study authors put it, with the idea that syringe exchange leads to more injecting. Several earlier studies in cities with moderate to high HIV prevalence reached the same conclusion.
Funding and Legal Landscape
Federal funding for syringe services programs has a complicated history. For decades, Congress barred any federal money from supporting them. That changed in December 2015, when the Consolidated Appropriations Act partially lifted the restriction. Under the updated rules, state and local health departments that already receive federal health funding can redirect some of those dollars to create or expand SSPs, but only if they can demonstrate an ongoing or potential outbreak of HIV or hepatitis C linked to injection drug use. One key limitation remains: federal funds still cannot be used to purchase the syringes themselves. That cost falls to state, local, or private funding.
Legal status varies by state. Some states explicitly authorize syringe services programs, others allow them through public health emergency declarations, and a handful still restrict or effectively ban them. The patchwork means access depends heavily on where someone lives, which is one reason the number of programs and the populations they serve remain unevenly distributed across the country.